ESR1 and invasive breast carcinoma: Testing for expression of ER, PR, and HER2/neu is now universally recommended in all invasive breast carcinoma patients that serve not only as prognostic biomarkers but also as predictive markers for determining adjuvant therapy (3, 19, 20).